Editas Medicine Receives Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Sickle Cell Disease
TipRanksGoldman Sachs Predicts Over 40% Rally for These 3 StocksA new wave of optimism is splashing onto the Street. Investment...
Designation
